Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $7.0 million.

  • Gain Therapeutics' Cash from Financing Activities rose 76966.94% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.2 million, marking a year-over-year decrease of 2986.41%. This contributed to the annual value of $13.0 million for FY2024, which is 293.27% up from last year.
  • Per Gain Therapeutics' latest filing, its Cash from Financing Activities stood at $7.0 million for Q3 2025, which was up 76966.94% from $2.5 million recorded in Q2 2025.
  • In the past 5 years, Gain Therapeutics' Cash from Financing Activities registered a high of $42.0 million during Q1 2021, and its lowest value of -$213795.0 during Q2 2021.
  • Its 5-year average for Cash from Financing Activities is $4.4 million, with a median of $778793.0 in 2023.
  • As far as peak fluctuations go, Gain Therapeutics' Cash from Financing Activities plummeted by 192572.48% in 2021, and later soared by 16111526.05% in 2023.
  • Gain Therapeutics' Cash from Financing Activities (Quarter) stood at -$9735.0 in 2021, then crashed by 121.69% to -$21582.0 in 2022, then surged by 44398.94% to $9.6 million in 2023, then tumbled by 75.81% to $2.3 million in 2024, then skyrocketed by 204.08% to $7.0 million in 2025.
  • Its last three reported values are $7.0 million in Q3 2025, $2.5 million for Q2 2025, and $2.4 million during Q1 2025.